Adults with active Crohn’s Disease needed for trial of investigational medication

IRB/UVA Tracking #
18943
Principal Investigator
Behm Brian,
Contact First Name

Harriette

Contact Last Name

Wheatley

Contact Email
Contact Phone
Official Trial Title
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn’s Disease
Study Description

The Department of Gastroenterology is investigating an experimental drug for Crohn’s Disease.

The purpose of the study is to evaluate the safety and effectiveness of an investigational medication for Crohn’s Disease.

Study involves 14 study visits at UVa over 60 weeks. Each visit will last about 2 hours and procedures include a colonoscopy, chest xray, blood draws and stool samples in addition to taking study pill/placebo pill at home.

Study-related procedures are provided free of charge.

Ages: Between 18 and 75 years

Compensation

up to $825